Uncategorized

Signum Surgical is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer.

2025-04-04T10:50:38+01:00

Signum Surgical, the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer. Ms. Burns’ appointment is a pivotal milestone for Signum, as the Company initiates commercialization of BioHealx, a first-of-its-kind medical device for the treatment of anal fistula, a painful and debilitating colorectal condition that affects one in 5,000 people worldwide. Read More

Signum Surgical is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer.2025-04-04T10:50:38+01:00

Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.

2025-04-04T10:42:27+01:00

Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, has been inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Read More

Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.2025-04-04T10:42:27+01:00

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology.

2025-03-19T11:32:46+00:00

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success of the SHINE study, the largest of its kind in prediabetes. The study demonstrated that Carb Fence™, an medical-grade, fast-acting liquid formula powered by SiPore®, effectively reduces long-term blood sugar levels HbA1c (A1C), improves glucose metabolism, and reduces body weight - while preserving muscle mass. These robust findings position Carb Fence™ as a pioneering medical food in the U.S., a category recognized by the FDA for the dietary management of diseases or conditions under physician supervision, as defined [...]

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology.2025-03-19T11:32:46+00:00

Dublin-based Bounce Insights raises €4.2 million to expand its AI-powered market research platform into the US

2024-12-13T09:46:43+00:00

Bounce Insights, an Irish startup specialising in AI-powered market research, has announced a €4.2 million funding round. This funding will fuel the company’s expansion into the US market, including the opening of a New York office to support its 25-person team and plans to triple its headcount globally by the end of 2026. Read more

Dublin-based Bounce Insights raises €4.2 million to expand its AI-powered market research platform into the US2024-12-13T09:46:43+00:00

AnaBio and Milky Mist India announce the launch of the first long-life dairy drink fortified with Anabio encapsulated probiotics.

2024-12-12T12:39:30+00:00

South Indian dairy company MilkyMist has teamed up with SIG and AnaBio Technologies to introduce what is claimed to be the world’s first long-life probiotic buttermilk in aseptic carton packs. The ground-breaking development, showcased at Gulfood Manufacturing 2024 in Dubai, represents a major breakthrough in the beverage industry, allowing probiotics to be incorporated into shelf-stable drinks in aseptic cartons for the first time. Read Article Here

AnaBio and Milky Mist India announce the launch of the first long-life dairy drink fortified with Anabio encapsulated probiotics.2024-12-12T12:39:30+00:00

First marketing approval in China for Cinclus Pharma

2024-12-12T12:25:05+00:00

Swedish clinical-stage drug developer Cinclus Pharma (STO: CINPHA), a specialist in treatments for gastric acid-related diseases, had picked up Chinese approval for linaprazan glurate. The outcome represents the firm’s first marketing approval in China. The approval by the National Medical Products Administration (NMPA) paves the way for commercialization in the People’s Republic of China in 2025. Read Article Here

First marketing approval in China for Cinclus Pharma2024-12-12T12:25:05+00:00

SymPhysis Medical secures €2.2m funding for cancer patient device

2024-10-10T16:43:09+01:00

Galway MedTech company SymPhysis Medical has secured €2.2m funding for the development of a device to address the condition of fluid in the chest of cancer patients. The medtech company will seek regulatory approval in the US for its device treating end-of-life cancer patients at the end of 2025. Business Post Article

SymPhysis Medical secures €2.2m funding for cancer patient device2024-10-10T16:43:09+01:00

Biggest impact on oral health since introduction of fluoride predicted as Sigrid Therapeutics announces market readiness of SiPore® Professional Care and Consumer Range Products

2024-07-10T17:45:04+01:00

Sigrid Therapeutics today announced the market readiness of SiPore® for both the professional and consumer oral health markets. Read Press Release here

Biggest impact on oral health since introduction of fluoride predicted as Sigrid Therapeutics announces market readiness of SiPore® Professional Care and Consumer Range Products2024-07-10T17:45:04+01:00

Signum Surgical’s BioHealx technology obtains FDA clearance

2024-07-10T17:30:33+01:00

Signum Surgical, a medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce that its BioHealxTM technology has been granted marketing clearance by the U.S. Food and Drug Administration (FDA), as a first-of-its-kind medical device for the treatment of anal fistula. Read Press Release here

Signum Surgical’s BioHealx technology obtains FDA clearance2024-07-10T17:30:33+01:00

Irish medtech firm Deciphex has signed a collaboration agreement with Novartis.

2024-05-16T13:48:48+01:00

Irish medtech firm Deciphex has signed a collaboration agreement with Novartis, the pharma giant, to develop artificial intelligence solutions to aid drug discovery and development. Read Full Article

Irish medtech firm Deciphex has signed a collaboration agreement with Novartis.2024-05-16T13:48:48+01:00
Go to Top